Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Shares Shorted Rose By 4.93%

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Corporate Logo

It was recorded an increase on Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)’s short interest with 4.93%. In December was announced ZYNE’s total 1.78 million short interest by FINRA. Previously was reported up change of 4.93% from 1.70 million shares. With Average volume 834,000, ZYNE’s former position will take 2 days to recover. Zynerba Pharmaceuticals Inc float short is 15.02%.

ZYNE hit $4.8 during the last trading session after $0.03 change.Currently Zynerba Pharmaceuticals, Inc. is uptrending after 9.92% change in last December 8, 2017. ZYNE has 116,227 shares volume. ZYNE underperformed by 5.70% the S&P500.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery.The firm is worth $84.61 million. The Company’s product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain.Currently it has negative earnings. The firm was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014.

For more Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) news released briefly go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Seekingalpha.com or Marketwatch.com. The titles are as follows: “Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock – GlobeNewswire” released on July 20, 2018, “Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors – GlobeNewswire” on April 16, 2018, “Zynerba: Does The Investment Case Still Hold? – Seeking Alpha” with a publish date: July 09, 2018, “Zynerba Pharmaceuticals: Undervalued Vs. GW Pharmaceuticals Plc – Seeking Alpha” and the last “Zynerba shares slide 17% after trial of cannabis-based skin patch fails to meet goals – MarketWatch” with publication date: July 05, 2018.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.